联合治疗复发性肝癌血液循环性肝癌细胞的变化及意义  

Changes and signinificance of circulating hepatocellular carcinoma cells in recurrent hepatocellular carciuoma patients after combined treatment

作　　者：刘扬[1] 吴孟超[1] 钱光相[1] 张柏和[1] 陈汉[1] 傅继梁[2] 黄长辉[3] 

机构地区：[1]第二军医大学东方肝胆外科医院,上海200433 [2]第二军医大学生物学教研室 [3]第二军医大学分子生物开放实验室

出　　处：《中华肝脏病杂志》2001年第1期40-41,共2页Chinese Journal of Hepatology

摘　　要：目的　探讨联合经肝动脉插管化疗栓塞术（ＴＡＣ）及无水酒精瘤内注射术（ＰＥＩ）治疗复发性肝癌周围静脉血液循环性肝癌细胞的变化及其意义。方法应用巢式ＲＴ－ＰＣＲ检测１９例复发性肝癌患者血液循环性肝癌细胞，并经ＴＡＣＥ及ＰＥＩ联合治疗观察其血液循环性肝癌细胞的变化。结果　血液循环性肝癌细胞表达阳性的７例复发性肝癌患者（３６８％），经ＴＡＣＥ及ＰＥＩ联合治疗后其血液循环性肝癌细胞均转为阴性（１００％，Ｐ＜０．０１）。结论　联合ＴＡＣＥ及ＰＥＩ治疗复发性肝癌可有效地杀灭血液中播散的循环性肝癌细胞，可预防肝癌再复发和转移的发生。Objective To study the changes and significance of circulating hepatocellular carcinoma cells in recurrent hepatocellular carcinoma (HCC) patients after combined treatment of transarterial chemo-embolization (TACE) and percutaneous ethanol injection (PEI). Methods We detected 19 blood samples from the recurrent HCC patients by nested RT-PCR to find out AFP mRNA before and after the treatment. Results There were 7 patients with AFP mRNA positive before treatment (36.8%), and none of patients with AFP mRNA positive after treatment. Conclusions Combined treatment of TACE and PEI can effectively eliminate circulating hepatocellular carcinoma cells and thereby prevent metastasis and recurrence of HCC.

关 键 词：肝癌细胞 聚合酶链反应 药物联合治疗 复发生肝癌 血液循环性 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]